- Home
- EVG vs TARA Comparison
EVG vs TARA Comparison
Compare EVG & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
EVG
Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | EVG | TARA |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.1M | 165.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EVG | TARA |
|---|---|---|
| Price | $10.82 | $5.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 49.4K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 8.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.13 | $2.77 |
| 52 Week High | $10.86 | $7.82 |
Technical Indicators
Market Signals| Indicator | EVG | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 34.05 | 42.14 |
| Support Level | $10.89 | $5.03 |
| Resistance Level | $11.03 | $6.37 |
| Average True Range (ATR) | 0.11 | 0.41 |
| MACD | -0.02 | -0.17 |
| Stochastic Oscillator | 14.14 | 12.80 |
Price Performance
Historical ComparisonAbout EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).